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Abstract	  The	  human	  Microbiota	   consists	  of	   the	  10-­‐100	   trillion	   symbiotic	  microbial	   cells	  harboured	  by	  each	  person	  that	  can	  therefore	  be	  considered	  as	  an	  ecosystem	  or	  a	  “super-­‐organism”.	  Microbiota	   is	   the	  microbial	   taxa	   associated	  with	   individuals	  while	  Microbiome	  is	  defined	  as	  the	  collective	  genomes	  of	  the	  microbes	  (bacteria,	  bacteriophage,	   fungi,	   protozoa	   and	   viruses)	   that	   live	   inside	   and	   on	   the	   human	  body.	  	  The	  gut	  Microbiota	  is	  increasingly	  regarded	  as	  an	  ‘invisible	  organ’	  of	  the	  human	  body	  and	  considered	  an	  important	  factor	  for	  host	  health,	  playing	  a	  major	  role	  in	  homeostasis.	  It	  is	  by	  far	  the	  most	  studied	  of	  all	  human	  ecosystems	  and	  arguably	  the	   one	   that	   most	   impacts	   global	   health	   status.	  	  Recently	   a	   lot	   of	   investigation	   has	   been	   dedicated	   to	   the	   field	   of	  Microbiota/Microbiome	   namely	   in	   what	   concerns	   the	   association	   between	  quantitative	   and	   qualitative	   changes	   in	   Microbiota/Microbiome	   and	   several	  pathologies.	  	  These	  pathologies	  include	  obesity	  and	  cardiovascular	  diseases,	  diabetes,	  central	  nervous	   system	   and	   degenerative	   diseases	   among	   many	   others.	  	  Various	   strategies	   can	   be	   used	   in	   order	   to	   modulate	   Microbiota	   alterations	  including	   administration	   of	   antibiotics,	   prebiotics	   and	   probiotics,	   nutritional	  interventions	   and	   faecal	   transplants.	   Even	   though	   these	   strategies	   seem	  promising	  there	  is	  still	  a	  great	  need	  for	  more	  robust	  studies	  that	  can	  verify	  their	  effectiveness	   and	   evaluate	   the	   real	   relation	   between	   Microbiota	   changes	   and	  diseases	  reviewed.	  	  
	  









1	  –	  INTRODUCTION	  	  Since	  Antoine	   van	   Leeuwenhoek	   first	   observed	   the	  microorganisms	   present	   in	  the	   human	  mouth	   in	   his	  microscope,	   in	   1676,	   a	   lot	   has	   evolved	   in	   the	   field	   of	  Microbiology.	  The	  late	  19th	  century	  witnessed	  the	  development	  of	  bacteria	  culture	  techniques,	  instrumental	  in	  microbiological	  research.	  In	  the	  1970s,	  strictly	  anaerobic	  culture	  techniques	  were	  developed.	  Yet,	  it	  was	  only	  after	  the	  advent	  of	  PCR	  and	  genome	  sequencing,	  in	  the	  1980s	  that	  the	  field	  of	  Microbiota	  took	  off.	  In	  fact,	  the	  first	  step	  of	   the	   Human	   Microbiome	   Project	   was	   the	   sequencing	   of	   intestinal	   bacteria	  genome,	  performed	  by	  Steven	  R.	  Gill.	  The	  initial	  phase	  of	  that	  project	  aimed	  to	  characterize	  the	  microbial	  communities	  from	  healthy	  individuals,	  across	  several	  different	  sites	  on	  the	  human	  body:	  nasal	  passages,	  oral	  cavity,	  skin,	  gastrointestinal	   tract,	  and	  urogenital	   tract	  using	  16S	  rRNA	   sequencing	   1.	   This	   delivered	   the	   first	   characterization	   of	   the	   microbial	  variety	  and	  the	  understanding	  of	  the	  human	  body	  less	  as	  an	  entity	  and	  more	  as	  an	  ecosystem.	  The	   continuous	   research	   on	   this	   field	   provided	   the	   first	   associations	   between	  microbial	  composition	  and	  some	  pathologies,	  the	  first	  being	  obesity,	  identifying	  organisms	  with	  either	  beneficial	  or	  harming	  properties.	  The	   concept	  of	  bacteria	   that	   is	  beneficial	   for	   the	  health	  was	   first	   supported	  by	  Elie	   Metchnikoff,	   regarding	   the	   milk	   fermentation	   bacteria,	   and	   was	   later	  supported	  by	  the	  work	  of	  Louis	  Pasteur.	  The	  actual	  metagenomic	  era	  is	  seeing	  a	  great	   expansion	   of	   knowledge,	   evidenced	   by	   the	   ever	   increasing	   number	   of	  dedicated	  publications,	  and	  is	  considered	  by	  many	  as	  a	  new	  age	  for	  microbiology.	  	  Microbiota	   is	   the	   microbial	   taxa	   associated	   with	   individuals.	   The	   human	  Microbiota	  consists	  of	  the	  10-­‐100	  trillion	  symbiotic	  microbial	  cells	  harboured	  by	  each	  person	  2.	  Microbiome	   is	   defined	   as	   the	   collective	   genomes	   of	   the	   microbes	   (bacteria,	  bacteriophage,	   fungi,	   protozoa	   and	   viruses)	   that	   live	   inside	   and	   on	   the	   human	  body.	  
Dysbiosis	   is	   the	   condition	   of	   having	   imbalances	   in	   the	  microbial	   communities	  either	  in	  or	  on	  the	  body	  and	  its	  pathological	  relevance	  is	  increasing	  consistently.	  Of	  all	  the	  human	  Microbiome	  ecosystems,	  the	  gut	  is	  by	  far	  the	  most	  diverse	  and	  probably	   the	  most	   influential	  on	   the	  global	  health	   status	  of	  an	   individual.	  Also,	  due	  to	   its	   importance	  and	  to	  study	  feasibility,	   it	   is	   the	  most	  thoroughly	  studied	  and	  that	  whose	  impact	  in	  pathophysiology	  is	  better	  understood.	  	  This	   review	   aims	   to	   characterize	   the	   changes	   in	   Microbiota	   and	   Microbiome	  occurring	  in	  several	  pathologies	  as	  well	  as	  to	  describe	  therapeutic	  interventions	  that	  aim	  to	  increase	  health	  through	  gut	  Microbiota	  modulation.	  	  2	  -­‐	  GUT	  MICROBIOME	  	  The	  gut	  Microbiota	  is	  increasingly	  regarded	  as	  an	  ‘invisible	  organ’	  of	  the	  human	  body	  and	  considered	  an	  important	  factor	  for	  host	  health	  3,	  playing	  a	  major	  role	  in	  homeostasis.	  It	  is	  by	  far	  the	  most	  studied	  of	  all	  human	  ecosystems	  and	  arguably	  the	  one	  that	  most	  impacts	  global	  health	  status.	  Mainly	  composed	  of	  bacteria	  (but	  also	  of	  other	  eukaryotes,	  archae,	  virus	  and	  phages),	  it	  concentrates	  mostly	  in	  the	  colon.	  The	   bacterial	   composition	   of	   the	   gut	   Microbiota	   changes	   along	   the	   GI	   length	  mainly	  due	   to	  host	   factors	  –	  pH,	  digestive	  enzymes,	  and	   immune	  system	  –,	  but	  also	   due	   to	   external	   factors	   –	   nutrients	   and	   environmental	   factors,	   and	   even	  microbial	  competition	  and	  synergies	  4.	  Over	   30	   bacterial	   phyla	   have	   been	   identified	   in	   the	   bacterial	   Microbiota	   with	  seven	  phyla	  accounting	  for	  its	  majority:	  Firmicutes,	  Bacteroidetes,	  Actinobacteria,	  
Cyanobacteria,	  Fusobacteria,	  Proteobacteria	  and	  Verrucomicrobia	  5.	  The	  first	  two	  are	  by	  far	  the	  most	  representative	  of	  the	  gut	  Microbiota.	  The	   gut	   Microbiota	   is	   established	   in	   early	   childhood	   and	   remains	   relatively	  stable	  throughout.	  Its	  composition	  is	  strongly	  influenced	  by	  factors	  like	  mode	  of	  birth,	   diet,	   diseases	   and	   medication	   6.	   Posterior	   imbalances	   or	   dysbiosis	   are	  associated	  with	  several	  pathologies	  and	  with	   the	  global	  quality	  of	  health	  of	   the	  individual.	  	  2.1	  -­‐	  GUT	  MICROBIOME	  AND	  CARDIOVASCULAR	  DISEASE	  	  
Cardiovascular	  diseases	  (CVDs)	  are	  a	  group	  of	  disorders	  of	  the	  heart	  and	  blood	  vessels	   that	   are	   currently	   the	   first	   cause	   of	   death	  worldwide.	  According	   to	   the	  World	  Health	  Organization	  (WHO),	  an	  estimated	  17.7	  million	  people	  died	   from	  CVDs	   in	   2015,	   representing	   31%	   of	   all	   global	   deaths	   7.	   Such	   numbers	   are	  expected	  to	  increase	  due	  to	  the	  marked	  incidence,	  prevalence	  and	  severity	  of	  the	  associated	  risk	  factors.	  Gut	   dysbiosis	   is	   associated	   with	   several	   pathologies	   that	   are	   a	   cause	   of	   or	   a	  consequence	   of	   cardiovascular	   disease,	   namely	   atherosclerosis,	   hypertension,	  heart	   failure,	   obesity,	   type	   2	   diabetes	   mellitus,	   chronic	   kidney	   disease	   and	  myocardial	   infarction.	   	   The	   ratio	   Firmicutes-­‐to-­‐Bacteroides	   is	   the	  most	   studied	  parameter	   and	   the	   one	   that	   shows	   the	   greater	   association	   with	   different	  cardiovascular	  diseases.	  Additionally,	   the	  metabolic	  potential	  of	   gut	  Microbiota	  has	  been	  identified	  as	  a	  contributing	  factor	  in	  the	  development	  of	  diseases	  8.	  Gut	  Microbiota-­‐host	   interactions	   occur	   through	   many	   pathways,	   including	  trimethylamine-­‐N-­‐oxide	  and	  the	  short-­‐chain	   fatty	  acids	  acetate,	  propionate	  and	  butyrate	  9.	  It	   is	   known	   that	   bacterial	   composition	   is	   affected	   by	   many	   parameters	   like	  lifestyle	   factors,	   including	   diet	   and	   concomitant	   diseases.	   However,	   the	   real	  impact	  of	  dysbiosis	  and	  its	  role	  as	  a	  biomarker	  or	  as	  a	  therapeutic	  target	  is	  yet	  to	  be	  fully	  disclosed.	  	  2.1.1.	  GUT	  MICROBIOME	  AND	  HIGH	  BLOOD	  PRESSURE	  	  Elevated	  blood	  pressure	  is	  defined	  as	  120	  to	  129	  mm	  Hg	  systolic	  with	  a	  diastolic	  pressure	  below	  80	  mm	  Hg;	  Stage	  1	  hypertension	  as	  130	  to	  139	  mm	  Hg	  systolic	  or	  80	  to	  89	  mm	  Hg	  diastolic;	  and	  Stage	  2	  hypertension	  as	  140/90	  mm	  Hg	  or	  higher	  10.	  High	   blood	   pressure	   is	   a	   complex	   and	  multifactorial	   condition	   influenced	   by	   a	  combination	  of	  genetic	  and	  environmental	   factors,	   including	  physical	   inactivity,	  obesity,	   high	   intake	   of	   fat,	   sugar	   and	   salt,	   smoking,	   and	   alcoholism	   11.	   On	   the	  opposite	  hand,	  high	  dietary	  intake	  of	  fruit,	  vegetables	  and	  fibre	  is	  associated	  with	  lower	  blood	  level	  pressures.	  
Since	  all	  these	  factors	  are	  also	  known	  to	  affect	  gut	  Microbiota	  composition,	  with	  a	   special	   emphasis	   on	   dietary	   choices	   12,	   it	   is	   reasonable	   to	   postulate	   that	   gut	  dysbiosis	   is	   linked	   to	   regulating	   blood	   pressure	   and	   to	   preventing	   or	   treating	  hypertension.	  In	  fact,	  one	  of	  the	  most	   important	  roles	  of	  the	  gut	  Microbiota	  is	  to	  yield	  energy	  and	   nutrients	   (metabolites	   and	   vitamins)	   by	   digesting	   dietary	   fibre,	   working	  symbiotically	  with	  the	  human	  body.	  The	   consumption	  of	   a	   diet	   richer	   in	   fibre	   causes	   an	   increase	   in	   gut	  Microbiota	  that	   generates	   short-­‐chain	   fatty	   acids,	   mainly	   by	   fibre	   fermentation	   13,	   and	   is	  associated	  with	   a	  decrease	   in	   the	   incidence	  of	   cardiovascular	  disease	   and	  high	  blood	  pressure	  levels	  14,	  even	  if	  the	  magnitude	  and	  type	  of	  effect	  is	  dependent	  on	  the	  type	  of	  ingested	  dietary	  fibre.	  The	  main	  short-­‐chain	  fatty	  acids	  that	  are	  produced	  are	  Acetate,	  Propionate	  and	  Butyrate	  and	  their	  relative	  percentage	  changes	  according	  to	  the	  qualitative	  and	  quantitative	  composition	  of	  the	  Microbiota	  present	  in	  the	  gut.	  Butyrate	   is	  mainly	   used	   locally	   by	   colonocytes	   to	  maintain	   the	   integrity	   of	   the	  intestinal	  barrier	  and	  to	  lower	  inflammatory	  levels.	  Acetate	  and	  small	  quantities	  of	   both	   Butyrate	   and	   Propionate	   (metabolised	   in	   the	   liver)	   enter	   systemic	  circulation	  and	  reach	  organs	  that	  regulate	  blood	  pressure.	  15	  The	  vast	  majority	  of	  the	  published	  studies	  that	  link	  gut	  dysbiosis	  with	  high	  blood	  pressure	  levels	  was	  performed	  in	  animal	  studies	  and	  therefore	  must	  be	  observed	  with	  caution	  when	  translating	  results	  and	  inferences	  to	  humans.	  The	   first	   studies,	   published	  more	   than	   40	   years	   ago,	   described	   that	   germ	   free	  rats	   presented	   a	   decreased	  microvasculature	   response	   to	   catecholamine	   and	   a	  lower	  cardiac	  output	  than	  control	  rats	  16.	  Other	   studies,	   performed	   in	   hypertension	   genetic	  models,	   reported	   changes	   in	  the	   composition	   of	   gut	   Microbiota	   composition	   (namely	   in	   the	   Firmicutes-­‐to-­‐
Bacteroidetes	  ratio,	  arguably	  the	  most	  described	  marker	  of	  dysbiosis),	  presenting	  a	   reduced	   number	   of	   species	   that	   produce	   Acetate	   and	   Butyrate,	   and	   an	  increased	  percentage	  of	  lactate	  producers	  17.	  The	  same	  research	  group	  performed	  Microbiota	  diversity	  analysis	  in	  a	  cohort	  of	  controls,	   a	   cohort	   of	   pre-­‐hypertensive	   and	   a	   cohort	   of	   patients	   with	   primary	  hypertension.	   Interestingly	   they	   found	   no	   significant	   differences	   between	  
Microbiota	   diversity	   for	   the	   pre-­‐hypertension	   and	   the	   primary	   hypertension	  cohorts,	  and	  did	  find	  that	  these	  groups	  presented	  a	  decreased	  microbial	  richness	  and	   diversity,	   a	   Prevotella-­‐dominated	   gut	   enterotype,	   a	   distinct	   metagenomic	  composition	  of	  reduced	  bacteria	  associated	  with	  healthy	  status	  and	  overgrowth	  of	   bacteria	   such	   as	   Prevotella	   and	   Klebsiella,	   and	   a	   disease-­‐linked	   microbial	  function	   18.	   	   The	   fact	   that	   pre-­‐hypertension	   and	   primary	   hypertension	   groups	  presented	   similar	   gut	  Microbiota	   patterns	   alerts	   us	   to	   the	   potential	   use	   of	   gut	  dysbiosis	  as	  an	  early	  marker	  for	  cardiovascular	  disease.	  	  In	   the	   same	   paper	   19,	   the	   authors	   conducted	   a	   faecal	   transplantation	   from	  hypertensive	   human	   donors	   to	   germ-­‐free	   mice,	   elevated	   blood	   pressure	   was	  observed	  to	  be	  transferrable	  through	  Microbiota,	  and	  the	  direct	  influence	  of	  gut	  Microbiota	  on	  blood	  pressure	  of	   the	  host	  was	  demonstrated.	  Facts	   like	  this	  not	  only	   strengthen	   the	   association	   between	   gut	   dysbiosis	   and	   hypertension,	   but	  also	   should	   be	   taken	   into	   account	   when	   conducting	   faecal	   transplantation	   in	  humans.	  	  The	  increase	  in	  blood	  pressure	  in	  spontaneously	  hypertensive	  rat	  was	  associated	  with	  gut	  pathology	  that	  included	  increased	  intestinal	  permeability	  and	  decreased	  tight	  junction	  proteins,	  but	  in	  this	  study	  pre-­‐hypertensive	  rats	  presented	  similar	  profiles	  to	  that	  of	  control	  ones,	  with	  Firmicutes-­‐to-­‐Bacteroidetes	  dysbiosis	  being	  evident	  only	  for	  the	  hypertensive	  group	  20.	  	  Reduced	  Microbiota	   richness	   had	   also	   been	  demonstrated	   in	   animal	  models	   of	  hypertension,	  like	  the	  angiontensin	  II	  induced	  hypertensive	  mice	  with	  a	  decrease	  in	  Bacteroidetes	  when	   compared	   to	   sham-­‐salt	  mice,	   but	   a	   higher	  prevalence	  of	  
Proteobacteria	  and	  Cyanobacteria	  17.	  	  	  The	  importance	  of	  salt	  in	  hypertension	  is	  well	  established.	  The	  proximal	  colon	  is	  a	  primary	   site	   for	  gut	  Microbiota	  and	  an	   important	   site	   for	  dietary	  absorption.	  The	   role	   played	   by	   gut	   Microbiota	   was	   investigated	   using	   rats	   genetically	  modified	   either	   to	   be	   sensitive	   to	   or	   resistant	   to	   high	   salt	   intake	   diets.	   These	  authors	  observed	  a	  gut	  Microbiota	  composition	  difference	  between	  the	  sensitive	  and	   the	   resistant	   strains,	   with	   a	   higher	   prevalence	   of	   Bacteroidetes	   for	   the	  
sensitive	  group,	  a	  lower	  level	  of	  faecal	  bacteria	  of	  the	  family	  Veillonellaceae	  and	  increased	   plasma	   acetate	   and	   heptanoate	   were	   features	   associated	   with	   the	  increased	   blood	   pressure	   observed	   in	   the	   sensitive	   rats	   given	   resistant	   rat	  Microbiota	   compared	   with	   the	   S	   rats	   given	   S	   rat	   Microbiota,	   indicating	   a	  plausible	  link	  between	  microbial	  content	  and	  blood	  pressure	  regulation	  18,19,20.	  	  A	   case-­‐control	   study	   of	   the	   association	   between	   Metabolome,	   the	   global	  collection	   of	   all	   low	   molecular	   weight	   metabolites	   that	   are	   produced	   by	   cells	  during	   metabolism,and	   Hypertension	   Risk	   identified	   multiple	   metabolites	  associated	   with	   hypertension	   risk.	   For	   example,	   higher	   levels	   of	   lyxose,	   a	  fermentation	   product	   of	   gut	   microbes,	   were	   associated	   with	   higher	   risk	   of	  hypertension,	  strengthening	   the	   thesis	   that	  gut	  Microbiome	  plays	  an	   important	  role	  in	  the	  pathogenesis	  of	  hypertension	  21.	  Besides	  those	  metabolites,	  short	  chain	  fatty	  acids	  produced	  by	  bacteria	  are	  also	  known	   to	   mediate	   arterial	   resistance	   22,	   which	   is	   consistent	   with	   findings	  indicating	   that	   Acetate	   and	   Propionate	   reduce	   blood	   pressure	   levels	   in	   animal	  models,	  mainly	  due	  to	  a	  combination	  of	  actions	  in	  renal	  mechanisms	  23.	  	  The	   association	   between	   gut	   dysbiosis	   seems	   to	   be	   ever	   more	   clear,	   even	   if	  causality	  or	  consequence	  is	  yet	  to	  be	  established	  and	  understood.	  More	  and	  more	  studies	  are	  being	  conducted	  in	  this	  field	  and	  there	  is	  also	  evidence	  being	  gained	  of	   prebiotics	   and	   probiotics	   impact	   in	   regulating	   blood	   pressure.	   Preliminary	  data	  also	  seems	  to	  suggest	  interaction	  between	  gut	  Microbiota	  composition	  and	  blood	  pressure	  drug’s	  effectiveness.	  	  2.1.2	  GUT	  MICROBIOME	  AND	  DYSLIPIDAEMIA	  AND	  ATHEROSCLEROSIS	  	  Dyslipidaemia	   is	   an	   elevation	   of	   plasma	   low-­‐density	   lipoprotein	   (LDL)	  cholesterol,	  triglycerides	  (TGs),	  or	  both,	  or	  a	  low	  high-­‐density	  lipoprotein	  (HDL)	  level.	  Due	  to	  the	  fact	  that	  gut	  Microbiota	  is	  directly	  involved	  in	  the	  lipid	  metabolism,	  it	  is	  understandable	  that	  it	  plays	  a	  role	  in	  dyslipidaemia.	  	  
The	  colonic	  fermentation	  of	  carbohydrates	  and	  fibre	  produces	  short-­‐chain	  fatty	  acids	  (SCFA),	  which	  may	  impact	  a	  number	  of	  physiological	  processes	  related	  to	  human	   energy	  metabolism,	   including	   satiety,	   hepatic	   lipogenesis,	   adipocyte	   fat	  deposition	  and	  thermogenesis	  24.	  Also,	  a	  variety	  of	  signalling	  molecules	  produced	  by	   gut	   bacteria	   potently	   affect	   hepatic	   lipid	   and	   bile	   metabolism,	   reverse	  cholesterol	   transport,	   energy	   expenditure,	   and	   insulin	   sensitivity	   in	   peripheral	  tissues,	  thus	  playing	  a	  major	  role	  in	  many	  metabolic	  pathways	  25.	  	  Associations	   have	   been	   established	   between	   gut	   Microbiota	   and	   the	   levels	   of	  serum	   triglycerides	   and	   HDL	   cholesterol,	   as	   well	   as	   between	   a	   total	   of	   34	  intestinal	  bacteria	  taxonomies	  and	  body	  mass	  index	  (BMI)	  and	  blood	  lipids.	  The	  gut	  Microbiome	  appears	  to	  make	  a	  significant	  contribution	  to	  the	  variance	  seen	  in	  individual	  BMI	  and	  to	  the	  blood	  levels	  of	  triglycerides	  and	  HDL,	  beyond	  that	  of	  clinical	   risk	   factors	   and	   genetics,	   whilst	   manifesting	   little	   effect	   on	   LDL	   or	   TC	  levels	  26.	  Other	   studies	   confirmed	   not	   only	   previously	   known	   associations	   between	  obesity	  and	  certain	  bacterial	  taxa	  (such	  as	  Akkermansia,	  Christensenellaceae,	  and	  
Tenericutes),	  but	  also	   that	  some	  of	   the	  associations	  with	  microbial	  composition	  were	   shared	   between	   BMI	   and	   levels	   of	   triglycerides	   and	   HDL	   and	   novel	  associations	  with	  Eggerthella,	  Pasteurellaceae,	  and	  Butyricimonas	  27.	  Interestingly,	  only	  weak	  correlations	  were	   found	  between	  Microbiota	  variation	  and	   total	   cholesterol	   or	   LDL	   cholesterol	   levels,	   suggesting	   that	   gut	  Microbiota	  intervenes	  more	  specifically	  in	  other	  lipoproteins	  25.	  	  Another	   consequence	   described,	   effects	   on	   reverse	   cholesterol	   transport	   –	   a	  crucial	   atheroprotective	   function	   of	   HDL	   –,	   could	   subsequently	   influence	   the	  development	  of	  atherosclerosis	  28.	  	  Modulation	   of	   gut	  Microbiota	   using	   different	   strategies	   has	   proved	   efficient	   in	  either	  repairing	  gut	  dysbiosis,	  but	  also	  in	  treating	  dyslipidaemias.	  Soluble	  fibres,	  like	  Polydextrose	  (PDX),	  present	  lipid	  lowering	  effects.	  PDX	  reduces	  triglycerides	  and	   cholesterol	   by	   influencing	   the	   gut	   Microbiota,	   which	   in	   turn	   modulates	  intestinal	  gene	  expression.	  In	  mice	  fed	  with	  western	  diet	  PDX	  promoted	  systemic	  changes	   via	   regulation	   of	   the	   gut	  Microbiota	   and	   gene	   expression	   in	   intestinal	  
tract	   29.	   Faecal	   transplants	   and	   the	  use	  of	   other	  prebiotics	   and	  probiotics	  have	  also	   proved	   to	   be	   effective.	   This	   suggests	   that	   the	   gut	   Microbiota	   can	   be	   a	  concomitant	   target	   for	   treating	   dyslipidaemias	   and	   other	   vascular	   related	  disease.	  	  Atherosclerosis	   is	   a	   condition	   where	   the	   arteries	   become	   narrowed	   and	  hardened	  due	  to	  a	  build-­‐up	  of	  plaque	  lining	  their	  walls	  and	  is	  directly	  related	  to	  lipid	  levels	  and	  inflammation.	  Gut	  Microbiota	   changes	   have	   also	   been	   found	  between	  patients	   suffering	   from	  atherosclerotic	   cardiovascular	   disease	   (ACVD)	   and	   healthy	   controls.	   An	  abundance	  of	  differences	  was	  found	  between	  the	  two	  groups	  in	  major	  genera	  of	  the	   gut	  Microbiome,	   such	   as	   a	   relative	   reduction	   in	  Bacteroides	   and	  Prevotella,	  enrichment	   in	   Streptococcus	   and	   a	   higher	   proportion	   of	   Enterobacteriaceae	  (including	  Escherichia	  coli,	  Klebsiella	  spp.,	   and	  Enterobacter	  aerogenes)	   in	  ACVD	  patients	  30.	  The	  same	  authors	  described	  a	  reduced	  potential	  for	  the	  synthesis	  of	  tetrahydrofolate	   and	   altered	  potential	   for	   homocysteine	  metabolism	   in	   the	   gut	  microbiome	  of	  ACVD	  patients	  compared	  with	  controls.	  Factors	   like	   trimethylamine	   N-­‐oxide	   (TMAO),	   trimethylamine	   (TMA)-­‐Lyases	  (choline,	   betaine,	   carnitine)	   and	   other	   bacterial	   virulence	   factors	   play	   an	  important	   role	   also	   on	   the	   severity	   and	   intensity	   of	   atherosclerotic	  cardiovascular	  disease.	  Dietary	  supplementation	  of	  mice	  with	  choline,	  TMAO	  or	  betaine	   promoted	   upregulation	   of	   multiple	   macrophage	   scavenger	   receptors	  linked	  to	  atherosclerosis,	  and	  supplementation	  with	  choline	  or	  TMAO	  promoted	  atherosclerosis	  31.	  Microbiota	   is	   involved	   in	   atherosclerosis	   via	   different	   pathways.	   Gut	  permeability	  and	   translocation	  of	  bacteria	  and	   their	  metabolites	   (LPS)	   into	   the	  circulation	   occur	   as	   a	   result	   of	   gut	   dysbiosis.	   The	   elevated	   levels	   of	   the	  circulating	  LPS	  promote	  inflammation	  and	  foam	  cell	  formation	  32.	  This	   increased	   knowledge	   of	   gut	   Microbiota	   changes	   and	   atherosclerotic	  cardiovascular	  disease	  opens	  space	  to	  identification	  of	  early	  disease	  biomarkers	  and	  to	  new	  therapeutic	  targets.	  	  2.1.3.	  GUT	  MICROBIOME	  AND	  MYOCARDIAL	  INFARCTION	  AND	  STROKE	  
	  Atherosclerosis,	  dyslipidaemias	  and	  a	  combination	  of	  environmental	  and	  genetic	  factors	  are	  on	  the	  genesis	  of	  events	  like	  myocardial	  infarction	  and	  stroke	  that	  are	  worldwide	  amongst	  the	  leading	  causes	  of	  morbidity	  and	  mortality.	  Since	   cardiovascular	   diseases	   are	   strongly	   influenced	   by	   dietary	   styles	   which	  also	  strongly	  affect	  the	  gut	  Microbiota	  and	  since	  gut	  Microbiota	  is,	  in	  turn,	  known	  to	  influence	  lipid	  metabolism,	   insulin	  resistance,	  and	  inflammation,	   it	   is	  of	   little	  surprise	   that	   there	   is	   an	   association	   between	   gut	   Microbiota	   and	   both	  myocardial	  infarction	  and	  stroke.	  In	   fact,	   Zunini	   Vahed	   et	   al	   32	   elegantly	   described	   disturbed	   Microbiota	   as	   an	  enemy	  for	  the	  cardiovascular	  system,	  responsible	  for	  an	  increased	  incidence	  and	  severity	  of	  cardiovascular	  disease.	  Trimethylamine	   N-­‐oxide	   induces	   platelets	   hyper-­‐reactivity	   and	   consequently	  creates	  a	  pro-­‐thrombotic	  status.	  It	  may	  also	  induce	  gut	  Microbiota	  dysbiosis.	  On	  the	  other	  hand,	  gut	  Microbiota	  plays	  a	  major	  role	  in	  the	  generation	  of	  TMAO	  via	  conversion	   of	   dietary	   nutrients	   that	   possess	   a	   TMA	   moiety	   (such	   as	   choline,	  phosphatidylcholine,	   and	   L-­‐carnitine)	   into	   TMA	   by	   specific	   microbial	   choline	  trimethylamine	  	  lyases	  8.	  	  	  A	  mechanistic	   link	   between	   the	   gut	  Microbiota	   and	   the	   severity	   of	  myocardial	  infarction	  has	  been	  reported	  in	  animal	  models	  where	  antibiotic-­‐induced	  changes	  in	   the	   abundance	   of	   individual	   groups	   of	   intestinal	   Microbiota	   dramatically	  altered	  the	  host’s	  metabolism.	  The	  most	  affected	  pathway	  was	  the	  catabolism	  of	  the	  aromatic	  amino	  acids	  phenylalanine,	  tryptophan	  and	  tyrosine	  and	  resulted	  in	  the	  decreased	  severity	  of	  an	  induced	  myocardial	  infarction	  33.	  Gut	   Microbiota	   also	   seems	   to	   attenuate	   post	   myocardial	   infarction	   events	   by	  means	   of	   modulating	   inflammatory	   and	   immune	   response,	   attenuating	   post	  infarction	   vulnerability	   to	   apoptosis	   and	   depression,	   and	   delaying	   post-­‐infarction	  heart	  failure	  32.	  Again,	   gut	  Microbiota	  modulation	   strategies	   can	  prove	   effective	   in	   successfully	  treating	  these	  pathologies.	  	  2.2	  GUT	  MICROBIOME	  AND	  OBESITY	  
	  World	   Health	   Organization	   defines	   overweight	   and	   obesity	   as	   abnormal	   or	  excessive	   fat	   accumulation	   that	   may	   impair	   health.	   Obesity	   is	   considered	   an	  epidemic	  disease	  in	  developed	  and	  developing	  countries	  and	  is	  escalating	  in	  all	  population	   groups.	   Some	   possible	   explanations	   include	   increases	   in	   energy	  intake,	  changes	  in	  the	  composition	  of	  diet,	  reduced	  physical	  activity,	  and	  changes	  in	  the	  gut	  Microbiome	  34.	  The	   relation	  between	  gut	  Microbiota	  and	  obesity	  has	  been	   the	   focus	  of	   several	  investigations.	   It	   has	   been	   shown	   that	   the	   gut	   Microbiota	   influences	   energy	  balance	  by	  producing	  SCFA	  from	  complex	  polysaccharides	  either	  by	  digestion	  or	  fermentation	  (together	  with	  residual	  proteins	  that	  cannot	  be	  digested	  by	  human	  enzymes;	   this	   also	   creates	   branched-­‐chain	   fatty	   acids,	   gases,	   and	   other	  metabolites).	   Acetate	   (C2),	   Propionate	   (C3)	   and	   Butyrate	   (C4)	   are	   the	   main	  products	  with	  impact	  on	  health	  35.	  	  	  Obese	   patients	   often	   present	  with	   intestinal	   dysbiosis,	   creating	   changes	   in	   the	  quali-­‐quantitative	   composition	   of	   intestinal	   commensal	   bacteria,	   reversible	  through	  weight	  loss.	  In	   obesity,	   gut	   Microbiota	   usually	   shows	   decreased	   diversity,	   a	   decreased	  
Bacteroidetes-­‐to-­‐Firmicutes	   ration	   (with	   increased	   capacity	   to	   harvest	   energy	  from	  diet),	  and	  altered	  fermentation	  products	  (mainly	  SCFA).	  It	   is	   also	   known	   that	   long-­‐term	   diet	   habits	   influence	   the	   composition	   of	   gut	  Microbiota	   36.	   Intestinal	   bacteria	   react	   to	   daily	   dietary	   fat	   and	   carbohydrates,	  changing	  their	  metabolic	  pattern.	  Still,	  the	  extent,	  mechanisms	  and	  consequences	  of	  a	  dietary	  shift	  remain	  unknown	  37.	  	  Such	  studies	  imply	  the	  participation	  of	  SCFA	  production	  in	  obesity	  (by	  sourcing	  extra	  energy).	  However,	  SCFA	  are	  also	  responsible	   for	  opposite	  mechanisms	  of	  energy	  expenditure,	  such	  as	  the	  production	  of	  anorectic	  hormones	  and	  appetite	  regulation,	  that	  may	  prevail	  in	  a	  non-­‐obese	  person.	  Furthermore,	   the	   chronic	   inflammation	   linked	   to	   obesity	   is	   associated	   with	  changes	  in	  Microbiota	  composition	  and	  intestinal	  permeability	  38,	  in	  mechanisms	  yet	   to	   be	   understood,	   but	   that	   can	   eventually	   be	   used	   to	   prevent	   and	   to	   treat	  these	  disorders.	  
	  For	   research	   purposes	   germ-­‐free	   mice	   were	   inoculated	   with	   normal	   gut	  microbial	   cells	   from	   conventionally	   raised	   mice,	   which	   resulted	   in	   a	   60%	  increase	   in	  body	   fat	   and	   insulin	   resistance,	   even	  with	  a	  27%	  reduction	   in	   food	  intake.	   They	   also	   found	   that	   bacterial	   colonization	   increased	   the	   storage	   of	  triglycerides	  in	  the	  adipocytes	  of	  the	  inoculated	  mice	  39.	  	  Other	  authors	  also	  performed	  a	   study	   in	  which	  germ-­‐free	  mice	  were	  colonized	  by	  faecal	  Microbiota	  of	  twins	  discordant	  for	  obesity	  or	  by	  cultured	  collection	  of	  lean	   or	   obese	   animals.	   Faecal	   cultured	   or	   uncultured	   faeces	   of	   obese	   animals	  originate	  significantly	  higher	  increase	  in	  body	  mass	  and	  adiposity	  than	  those	  of	  lean	  animals,	  whereas	  transplanted	  Microbiota	  of	  lean	  animals	  was	  correlated	  to	  higher	   quantity	   of	   SCFA	   in	   lean	   animals.	   When	   the	   animals	   were	   cohoused	  (obese	   and	   lean)	   the	   obese	   animals	   stopped	   their	   body	  weight	   gain	  modifying	  also	  their	  Microbiota	  profile	  like	  lean	  animals	  (increasing	  Bacteroides).	  The	  study	  was	  also	  conducted	  under	  2	  types	  of	  diet	  (low	  saturated	  fat	  and	  high	  saturated	  fat).	  The	  bacterial	  invasion	  colonization	  and	  phenotype	  change	  only	  occur	  in	  low	  saturated	   fat	   diet	   revealing	   a	   diet-­‐dependent	   mechanism	   between	   diet	   and	  Microbiota	  40.	  Interestingly,	  not	  only	  does	   the	  Microbiota,	  but	  also	   the	  Mycobiota	  –	  related	   to	  the	  fungal	  composition	  –,	  seem	  to	  be	  altered	  in	  obese	  individuals	  41.	  	  Even	   though	   these	   studies	   are	   quite	   promising	   it	   should	   be	   stressed	   that	   they	  were	  conducted	  in	  vitro	  or	  in	  animals	  and	  that	  translation	  to	  humans	  is	  hard	  and	  should	   be	   taken	   carefully.	   Nevertheless,	   strategies	   that	   modulate	   the	   gut	  microbial	   composition	  will	   be	   of	   increasing	  utility	   for	   the	   treatment	   of	   obesity	  and	  are	  expected	  to	  enter	  the	  clinical	  practice	  during	  the	  next	  years.	  	  2.3	  GUT	  MICROBIOME	  AND	  DIABETES	  	  Diabetes	   is	   a	  worldwide	   disease	  whose	   incidence	   has	   been	   increasing	   steadily	  over	  the	  last	  decades.	  Diabetes	  is	  highly	  influenced	  by	  diet	  and	  intimately	  related	  
to	   other	   pathologies	   described	   in	   this	   review	   and,	   therefore,	   expectedly	  associated	  with	  gut	  dysbiosis.	  Gut	  Microbiota	  interferes	  with	  diabetes	  pathogenesis	  in	  several	  ways,	   including	  energy	  metabolism,	  gut	  permeability,	  metabolic	  endotoxemia	  and	  by	  interacting	  with	  the	  immune	  system	  42.	  	  The	   gut	  Microbiota	   of	   patients	  with	   type	   2	   diabetes	   (T2DM)	   shows	   decreased	  levels	  of	  butyrate-­‐producing	  bacteria	  (e.g.	  F.	  prausnitzii)	  and	  increased	  levels	  of	  
Firmicutes	   and	   Proteobacteria	   43.	   These	   changes	   are	   accompanied	   by	   an	  increased	  expression	  of	  the	  Microbiota	  genes	  that	  enhance	  oxidative	  stress	  and	  inflammation	   44.	   Likewise,	   the	   altered	   levels	   of	   SCFA	   have	   implications	  concerning	  the	  inflammatory	  status.	  The	   decreased	   levels	   of	   Bifidobacteria	   stimulate	   the	   secretion	   of	   GLP1	   and	  peptide	  YY	  that	  decrease	  resistance	  to	  insulin	  and	  enhance	  the	  functionality	  of	  β	  cells.	   These	   bacteria	   are	   also	   known	   to	   reduce	   intestinal	   permeability	   45.	   The	  marked	   increase	   in	   gut	   permeability,	   together	   with	   differences	   in	   Microbiota	  composition,	   has	   also	   been	   associated	   with	   the	   pre-­‐pathological	   condition	   of	  Type	  1	  Diabetes	  T1DM	  46.	  An	  increase	  in	  gut	  permeability	  was	  similarly	  observed	  in	  T2DM	  patients,	  a	  situation	  that	  promotes	  endotoxemia	  and	  an	  increase	  of	  the	  systemic	  levels	  of	  LPS,	  inducing	  a	  deleterious	  continuous	  inflammatory	  state	  47.	  
Firmicutes	   and	   Actinobacteria	   metabolize	   choline,	   producing	   metabolites	  demonstrated	   to	   induce	   Diabetes.	   The	   same	   Firmicutes	   are	   associated	   with	   a	  decrease	   in	   the	   levels	   of	   secondary	  biliary	   acids	   that	   play	   an	   insulin	   sensitizer	  role	  48.	  	  T1DM	  	  is	  also	  associated	  with	  gut	  Microbiota	  changes.	  	  Faecal	  analysis	  from	  these	  patients	   showed	   decreased	   butyrate-­‐producing	   bacteria	   and	   less	   butyryl-­‐CoA	  transferase	   genes	   (with	   a	   marked	   decrease	   in	   plasma	   levels	   of	   acetate	   and	  propionate).	  The	  levels	  of	  strains	  Christensenella	  and	  Subdoligranulum	  correlated	  with	  glycemic	  control,	  inflammatory	  parameters	  and	  SCFA	  49.	  Children	  with	  beta-­‐cell	   autoimmunity	   have	   also	   shown	   low	   abundance	   of	   butyrate-­‐producing	  bacteria	   and	   increased	   abundance	   of	  members	   of	   the	  Bacteroidetes	   phylum	   in	  faecal	  Microbiota	  50.	  
	  Interestingly,	   metformin,	   a	   drug	   used	   in	   the	   treatment	   of	   diabetes,	   also	  modulates	  gut	  Microbiota	  51.	  Compared	   to	   participants	   without	   diabetes,	   participants	   with	   diabetes	   taking	  metformin	   had	   higher	   relative	   abundance	   of	   Akkermansia	   muciniphila,	   a	  Microbiota	  known	  for	  mucin	  degradation,	  and	  several	  gut	  Microbiota	  known	  for	  the	   production	   of	   SCFAs,	   including	   Butyrivibrio,	   Bifidobacterium	   bifidum,	  
Megasphaera,	  and	  an	  operational	  taxonomic	  unit	  of	  Prevotella	  52.	  	  The	  association	  between	  gut	  Microbiota	  changes	  and	  Diabetes	  opens	  space	  not	  only	   to	   early	   disease	   biomarkers,	   but	   also	   to	   new	   therapeutic	   strategies,	  including	   the	   use	   of	   prebiotics,	   probiotics	   and	   faecal	   transplantation.	   Again,	  further	  and	  more	  robust	  clinical	  studies	  are	  necessary.	  	  2.5	  GUT	  MICROBIOME	  AND	  CHRONIC	  KIDNEY	  DISEASE	  	  Kidney	   disease	   is	   closely	   linked	   to	   cardiovascular	   disease	   and	   is	   generally	  associated	  to	  a	  poorer	  prognosis	  of	  the	  latter.	  Chronic	   kidney	   patients’	   gut	   Microbiota	   is	   significantly	   different	   from	   that	   of	  healthy	   controls,	   with	   an	   increase	   in	   pathogenic	   flora	   compared	   to	   symbiotic	  flora	  53.	  The	  most	  frequently	  described	  changes	  in	  the	  gut	  Microbiome	  of	  these	  patients	  include	  a	  reduction	  of	  the	  Bifidobacteriaceae	  and	  Lactobacillaceae	   levels	  and	  an	  increase	  of	  the	  Enterobacteriaceae	  levels	  54.	  Gut	   dysbiosis,	   responsible	   for	   a	   disruption	   of	   the	   intestinal	   epithelial	   barrier	  complex	   can	   then	   play	   an	   important	   part	   in	   the	   development	   of	   systemic	  inflammation	   by	   enabling	   the	   influx	   of	   endotoxins	   and	   other	   noxious	   luminal	  contents	   into	   systemic	   circulation	   55.	   Such	   contents	   include	   metabolites	   like	  ammonia,	   indoxyl	   sulphate	   and	   p-­‐cresyl	   sulphate	   –	   associated	   with	   poor	  cardiovascular	   outcomes	   56	   –,	   and	   some	   products	   of	   the	   fermentation	   of	  undigested	   foods	   like	   sulphates,	   mainly	   associated	   with	   the	   family	   of	  tryptophanases	  of	  the	  phylum	  Bacteroides.	  
TMAO,	   a	   gut-­‐microbial-­‐dependent	   metabolite	   of	   dietary	   choline,	  phosphatidylcholine	   (lecithin),	   and	   L-­‐carnitine,	   is	   elevated	   in	   chronic	   kidney	  disease	   and	   is	   also	   a	   good	   biomarker	   for	   cardiovascular	   disease,	   as	   it	   is	   an	  important	  regulator	  of	  fibrosis	  57.	  	  Modulation	  of	  the	  gut	  Microbiome	  composition	  in	  chronic	  kidney	  disease,	  either	  by	   prebiotics,	   probiotics	   or	   even	   selective	   antibiotics,	   may	   contribute	   to	   a	  decreased	   accumulation	   of	   gut-­‐derived	   uremic	   toxins,	   high	   circulating	   level	   of	  lipopolysaccharides	  and	  immune	  deregulation,	  all	  of	  which	  play	  a	  critical	  role	  in	  the	  pathogenesis	  of	  chronic	  kidney	  disease	  and	  its	  complications	  58.	  	  2.6	  GUT	  MICROBIOME	  AND	  LIVER	  DISEASE	  	  Due	   to	   its	   anatomical	   location	   and	   physiological	   activity,	   the	   liver	   is	   in	   a	   key	  position	   to	   interact	   with	   gut	  Microbiota	   and	   the	  metabolites	   it	   generates.	   The	  liver	  receives	  70%	  of	  its	  blood	  supply	  from	  the	  intestine,	  via	  the	  portal	  vein,	  and	  bile	   acids	   have	   been	   shown	   to	   facilitate	   the	   communication	   between	   the	  intestine	  and	  the	  liver	  59.	  Of	  all	  liver	  pathologies,	  non-­‐alcoholic	  fatty	  liver	  disease	  appears	  to	  be	  one	  of	  the	  most	  directly	  associated	  with	  gut	  dysbiosis.	  Non-­‐alcoholic	   fatty	   liver	   disease	   (NAFLD),	   the	   most	   common	   liver	   disease	   in	  developed	  countries,	  has	  two	  main	  clinical	  phenotypes:	  non-­‐alcoholic	  fatty	  liver	  (hepatic	   steatosis	   with	   minimal	   lobular	   inflammation)	   and	   non-­‐alcoholic	  steatohepatitis	  (NASH,	  ballooning	  hepatocellular	  injury	  and	  an	  initial	  distinctive	  fibrosis	  pattern	  of	  perisinusoidal	  fibrosis	  surrounding	  the	  central	  veins	  60).	  It	  has	  been	   described	   as	   directly	   related	   to	   other	   pathologies	   like	   the	   metabolic	  syndrome,	  diabetes,	  and	  a	  combination	  of	  genetic	  and	  environmental	  factors	  like	  diet	  and	  lifestyle	  61.	  	  The	  gut	  Microbiota	  has	  been	  linked	  to	  non-­‐alcoholic	  fatty	  liver	  disease	  in	  several	  ways.	  Altered	  gut	  Microbiota	  can	  activate	  the	  innate	  immune	  system,	  as	  it	   is	  an	  inducer	   of	   proinflammatory	   T	   helper	   17	   cells	   and	   regulatory	   T	   cells	   in	   the	  
intestine	  61;	  it	  can	  also	  make	  the	  intestinal	  barrier	  more	  permeable,	  allowing	  the	  passage	  of	  bacterial	  products	  into	  the	  blood	  stream	  62.	  	  Changes	  in	  gut	  Microbiome	  may	  also	  be	  the	  direct	  cause	  of	  hepatic	  inflammation.	  On	  the	  one	  hand,	  increased	  populations	  of	  gut	  Enterobacteriales	  and	  Escherichia	  
coli	   generate	   LPS	   63	   which	   in	   turn	   interact	   with	   Toll-­‐like	   receptors	   (TLRs),	  ultimately	   inducing	   cellular	   death;	   on	   the	   other	   hand,	   the	   previously	   referred	  increase	   in	   intestinal	   permeability	   raises	   the	   endotoxins	   load	   in	   portal	  circulation,	   promoting	   hepatic	   inflammation	   64.	   This	   constant	   inflammation	   is	  responsible	  for	  activating	  the	  inflamassome	  in	  a	  two-­‐step	  process	  that	  generates	  a	  heavy	  hepatic	  inflammatory	  response	  65.	  	  	  Another	   crucial	   factor	   in	   liver	   steatosis	   is	   obesity,	   also	   well	   connected	   to	   gut	  dysbiosis	   and	   to	   changes	   in	   microbial	   induced	   metabolism	   (as	   described	  elsewhere	  in	  this	  review).	  The	  heavy	  lipid	  load	  associated	  with	  obesity	  acts	  as	  a	  cell	   stress	   inducer	   that	   activates	   the	   immune	   system.	   Also	   contributing	   to	   gut	  dysbiosis	   are	   the	   increased	   dietary	   levels	   of	   carbohydrates	   and	   fat,	   leading	   to	  lesser	   microbial	   diversity	   and	   to	   decreased	   Bacteroidetes	   levels	   relative	   to	  
Firmicutes	   66.	   Furthermore,	   the	   chronic	   inflammation	   linked	   to	   obesity	   is	  associated	  with	   changes	   in	  Microbiota	   composition	   and	   intestinal	   permeability	  38,	   in	   mechanisms	   yet	   to	   be	   understood,	   but	   that	   can	   eventually	   be	   used	   to	  prevent	  and	  treat	  this	  type	  of	  diseases.	  Additionally,	  in	  processes	  directly	  linked	  to	   the	   obesity	   pathways,	   exercise	   has	   demonstrated	   to	   be	   an	   effective	   non-­‐pharmacological	  treatment	  for	  NAFLD.	  	  Hepatic	  fibrosis	  is	  the	  main	  component	  of	  tissue	  remodelling	  eventually	  leading	  to	  cirrhosis,	  condition	  in	  which	  the	  liver	  does	  not	  function	  properly	  due	  to	  long-­‐term	  damage.	   The	   process	   of	   fibrosis	   is	   linked	   to	   the	  Microbiota	   again	   via	   the	  TLR	  that	  not	  only	  signal	  for	  an	  increased	  expression	  of	  chemokines	  and	  adhesion	  molecules,	  but	  also,	  when	  activated,	  down-­‐regulate	  the	  activin	  membrane	  bound	  receptor	   (BAMBI)	   and	   remove	   the	   fibrogenic	   brake	   thus	   facilitating	   disease	  progression	  67.	  	  
Many	  studies	   revealed	  differences	   in	  Microbiota	   composition	  between	  controls	  and	  patients	  with	  fatty	  liver	  disease.	  While	  Bacteroidetes	  and	  Firmicutes	  remain	  the	   dominant	   phyla	   among	  NAFLD	  patients,	   their	   proportional	   abundance	   and	  genera	  detection	  vary	  among	  different	  studies	  68.	  Proteobacteria	  seem	  to	  play	  a	  protective	   role	   regarding	   steatosis	   while	   bacteria	   from	   the	   Firmicutes	   phylum	  are	   correlated	   to	  higher	   fatty	   liver	  disease	   risk	   69.	   	  Different	   studies	  associated	  
Bacteroides	   to	   NASH	   and	  Ruminococcus	   to	   significant	   fibrosis.	   NAFLD	   severity	  associates	   with	   gut	   dysbiosis	   and	   a	   shift	   in	   metabolic	   function	   of	   the	   gut	  Microbiota	  70.	  Several	   other	   studies	  demonstrated	  an	  association	  between	   changes	   in	   the	   gut	  Microbiome	  and	  liver	  disease.	  It	  should	  however	  be	  emphasized	  that	  association	  is	   very	   different	   from	   causality	   and	   from	   a	   complete	   understanding	   of	   the	  underlying	   mechanisms	   and	   pathological	   pathways.	   Also	   many	   of	   the	   studies	  were	  performed	   either	   in	   animal	  models	   or	   in	   small	   human	   cohorts	   and	  using	  different	   methods;	   therefore,	   translation	   to	   clinic	   should	   be	   cautiously	  performed.	  That	   said,	   it	   is	   unequivocal	   that	   gut	   Microbiota	   analysis	   adds	   information	   to	  classical	  predictors	  of	  NAFLD	  severity	  and	  suggests	  novel	  metabolic	   targets	   for	  pre-­‐/probiotics	  therapies.	  Strategies	  like	  the	  increase	  in	  the	  consumption	  of	  fibre	  like	  pectin	  or	  probiotic	  treatment	  have	  been	  successfully	  studied	  62,	  but	  are	  yet	  far	   from	   being	   used	   standardly	   in	   the	   clinics.	   Absorbable,	   enteral-­‐active	  antibiotics	   like	   polymixin	   B	   and	   neomycin	   have	   also	   been	   studied	   for	   the	  treatment	   of	   dysbiosis	   and	   influence	   the	   outcome	   of	   chronic	   liver	   disease	   or	  cirrhosis	  71.	  Probiotics	  like	  lactobacillus	  are	  the	  components	  of	  many	  commercially	  available	  multispecies	   formulations	   such	   as	   VSL#3.	   In	   the	   rat	   gut,	   VSL#3	   fortifies	   the	  intestinal	  barrier	  by	  increasing	  the	  amount	  of	  secreted	  mucus	  and	  upregulating	  Muc2	  in	  the	  colon	  and	  occludin	  levels	  in	  the	  ileum	  72.	  Faecal	  transplants,	  however	  controversial,	  have	  also	  demonstrated	   to	  be	  effective	  and	  helpful	  when	  dealing	  with	  fatty	  liver	  disease.	  	  By	  now,	   it	   is	  clear	  that	  gut	  Microbiome	  plays	  an	   important	  role	   in	   liver	  disease	  even	   if	   the	   pathophysiological	   mechanisms	   are	   not	   yet	   fully	   understood.	  	  
Precision	  medicine	  and	  the	  targets	  and	  prevention	  methods	  that	  will	  arise	  from	  the	  continuous	  study	  of	  this	  area	  will	  certainly	  bring	  new	  therapeutic	  tools	  in	  the	  next	  years.	  	  2.7	  GUT	  MICROBIOME	  AND	  INTESTINAL	  DISEASE	  	  The	  effect	  of	  gut	  Microbiota	  dysbiosis	  in	  intestinal	  disease	  is	  probably	  the	  most	  logical,	  due	  to	  the	  local	  effect	  of	  the	  Microbiota.	  	  The	  best	  example	  that	  comes	  to	  mind	   is	   diarrhoea,	   a	   pathology	   in	   which	   gut	   Microbiota	   plays	   a	   major	   role	   in	  several	  ways,	  not	  only	  as	  cause,	  but	  also	  with	  protective	  effects	  73.	  Another	  frequent	  intestinal	  problem	  is	  constipation.	  Growing	  evidence	  indicates	  that	   alterations	   of	   intestinal	   Microbiota	   may	   contribute	   to	   constipation	   and	  constipation-­‐related	   symptoms,	   namely	   by	   modulating	   gut	   mobility	   74.	  Differences	   in	   the	   composition	   of	   the	   intestinal	   Microbiota	   have	   been	  demonstrated	  when	  constipated	  patients	   and	  healthy	   controls	  were	   compared.	  Probiotics	   are	   frequently	   and	   successfully	   used	   for	   constipation	   treatment	   or	  prevention.	  	  Several	   studies	   have	   reported	   differences	   between	   the	   Microbiota	   of	  inflammatory	   bowel	   disease	   (IBD;	   like	   Crohn	   disease	   and	   ulcerative	   colitis)	  patients	   and	   healthy	   subjects.	   A	   lower	   microbial	   diversity	   was	   found	   in	   IBD	  patients	   with	   an	   emphasis	   in	   a	   decrease	   of	   the	   Firmicutes	   quantity	   and	   an	  increase	  in	  the	  taxa	  belonging	  to	  the	  Proteobacteria	  phylum,	  generally	  associated	  with	  an	  increase	  in	  facultative	  anaerobes	  75.	  The	  reduction	  in	  this	  species	  lowers	  the	   production	   of	   SCFA	   increase	   regulatory	   T	   cells,	   which	   support	   immune	  tolerance	  and	  also	  have	  anti-­‐inflammatory	  effects.	  This	  outgrowth	  of	  facultative	  anaerobic	   organisms	   may	   be	   driven	   by	   a	   change	   in	   the	   gut	   redox	   potential	  associated	   to	   the	   chronic	   inflammatory	   status	   76.	   A	   special	   role	   seems	   to	   be	  played	  by	  F.	  Prausnitzii,	  known	  to	  induce	  the	  production	  of	  IL-­‐10	  and	  inhibit	  the	  production	   of	   inflammatory	   cytokines,	   such	   as	   IL-­‐12	   and	   IFN-­‐γ	   77,	   whose	  significantly	   lower	   levels	   in	   IBD	   lead	   to	   an	   increased	   probability	   of	   disease	  recurrence.	  Colorectal	  cancer,	  another	  high	  prevalence	  intestinal	  pathology,	   is	  also	  strongly	  influenced	   by	   gut	  Microbiota	   78.	   This	   paper	   addresses	   the	   influence	   of	   dietary	  
patterns,	   fibre	   consumption,	   dietary	   supplements	   and	   concomitant	   disease	   on	  the	  Microbiota	  composition,	  and	  studied	  bacterial	  metabolites	  and	  how	  they	  can	  disrupt	  the	  gut	  barrier	   integrity	  and	  challenge	  immune	  homeostasis,	   increasing	  the	  probability	  of	  cancer.	  	  The	  ever	  growing	  knowledge	  on	  gut	  Microbiota	  and	  its	  association	  with	  several	  intestinal	  pathologies	  opens	  new	  space	  for	  the	  identification	  of	  early	  biomarkers	  and	   for	   new	   therapeutic	   targets	   and	   strategies	   that	  will	   likely	   increase	   the	   life	  quality	  of	  these	  patients.	  Arguably	   the	   most	   successful	   case	   of	   treating	   intestinal	   disease	   using	   gut	  Microbiota	  is	  the	  treatment	  of	  multi-­‐resistant	  Clostridium	  difficile	  infection	  (CDI)	  using	   faecal	   Microbiota	   transplantation.	   CDI	   is	   a	   worldwide	   leading	   cause	   of	  mortality	  and	  morbidity	  and	  is	  becoming	  more	  and	  more	  resistant	  to	  antibiotics.	  This	  procedure,	  not	  yet	  fully	  regulated	  by	  the	  medicines	  agencies,	  has	  proven	  to	  be	   extremely	   effective	   in	   cases	   where	   administration	   of	   antibiotics	   failed.	  	  Strategies	   for	   performing	   effective	   treatments	   using	   faecal	   transplants	   were	  described	  in	  detail	  in	  papers	  like	  the	  ones	  referred	  by	  Dowle	  79	  and	  range	  from	  colonoscopy	   administration	   of	   enemas	   to	   oral	   administration	   of	   lyophilized	  contents	  inserted	  in	  capsules.	  	  Faecal	  Microbiota	   transplantation	   (FMT)	   is	   emerging	   as	   a	   treatment	   option	   in	  the	  United	  States	  of	  America	  and	  in	  Europe,	  and	  a	  conference	  consensus	  paper	  80	  was	  recently	  published	  on	  this	   thematic.	   In	  the	  supplement	  of	   that	  paper	  other	  applications	  for	  FMT	  are	  evaluated	  even	  if	  they	  are	  not	  as	  strongly	  adequate	  as	  for	   refractory	   CDI	   treatment.	   These	   include	   Crohn	   disease	   and	   Irritable	   Bowel	  Syndrome.	  	  	  2.8	  GUT	  MICROBIOME	  AND	  CNS	  RELATED	  DISEASES	  	  The	  connection	  between	  the	  gut	  and	  the	  central	  nervous	  system	  may	  not	  appear	  to	   be	   a	   direct	   one,	   but	   since	   the	   definition	   of	   the	   so-­‐called	   gut-­‐brain	   axis	   it	   is	  becoming	  more	  and	  more	  discussed	  and	  studied.	  
The	   first	   time	   an	   association	   between	   gut	   Microbiota	   and	   brain	   disease	   was	  reported	  was	   in	   the	   early	   20th	   century,	  when	   the	   administration	   of	   lactic	   acid	  was	  tested	  in	  the	  treatment	  of	  depressive	  symptoms	  81.	  Perhaps	   the	  most	   evident	   established	   connection	  was	   between	   gut	  Microbiota	  and	  stroke/ischemic	  brain	  damage.	  As	  previously	  described,	  these	  patients	  may	  present	   some	   Microbiota	   alterations	   (namely	   decreased	   diversity,	   decreased	  levels	   of	  Bacteroides,	   increased	  Atopobium	   levels	   and	   changes	   in	   the	  microbial	  metabolism	  82),	  all	  of	  which	  are	  responsible	  for	  an	  increase	  in	  gut	  permeability,	  with	  consequent	  systemic	   inflammation	  and	   increased	  risk	  of	   infection,	  as	  well	  as	  an	  increased	  risk	  for	  thrombosis,	  due	  to	  an	  increase	  in	  the	  levels	  of	  TMAO83.	  Also,	   the	   composition	   of	   gut	   Microbiota	   is	   likely	   to	   affect	   the	   level	   of	  neuroinflammation	  by	  modulating	  T	  Cells	  and	  IL-­‐17	  levels	  84.	  	  Gut	   Microbiota	   is	   known	   not	   only	   to	   intervene	   in	   the	   synthesis	   of	   GABA,	  noradrenaline	   and	   dopamine,	   but	   also	   in	   the	   production	   of	   SCFA,	   that	   also	  present	  neuroactive	  actions.	  The	  fact	  that	  gut	  Microbiota	  plays	  such	  a	  key	  role	  in	  modulating	  neurotransmitters	  helps	  explain	  the	  fact	  that	  gut	  dysbiosis	  interfere	  in	  disorders	  like	  anxiety	  and	  depression.	  Neurotransmitters	  play	  a	  major	  role	  in	  several	  central	  nervous	  related	  diseases.	  Gut	   Microbiota	   dysbiosis	   has	   been	   reported	   in	   preclinical	   data	   85	   and	   also	   in	  patients	   diagnosed	   with	   depression	   86,	   namely	   by	   a	   noticeable	   decrease	   in	  microbial	  diversity.	  Prebiotics	  like	  galactooligosaccharide	  (GOS)	  have	  been	  found	  to	   be	   effective	   in	   reducing	   activation	   of	   the	   preclinical	   models	   of	   anxiety	   and	  depression	  and	  also	  in	  lowering	  cortisol	  levels	  in	  human	  volunteers	  87.	  Probiotics	  like	  B.	  longum	  effectively	  increased	  scores	  of	  depression	  even	  if	  it	  did	  not	  affect	  anxiety	   levels	  88.	  Evidence	  of	   the	  association	  between	  gut	  Microbiota	  and	  other	  psychiatric	  disorders	  was	  also	  found	  during	  faecal	  transplant	  procedures	  89;	  yet,	  there	  is	  still	  need	  for	  more	  robust	  clinical	  data.	  Attention-­‐deficit/hyperactivity	   disorder	   (ADHD)	   is	   associated	   with	  abnormalities	  in	  dopamine	  neurotransmission.	  The	  role	  of	  gut	  Microbiota	  is	  not	  clear,	   but	   a	   nominal	   increase	   in	   the	   Bifidobacterium	   genus	   was	   observed	   in	  ADHD	   cases	   with	   metagenomic	   revealing	   an	   increase	   in	   the	   bacterial	   gene	  
functionality	  encoding	  cyclohexadienyl	  dehydratase,	  an	  enzyme	   involved	   in	   the	  synthesis	  of	  phenylalanine,	  a	  dopamine	  precursor	  90.	  	  Gut	  Microbiota	  dysbiosis	   is	  also	  associated	  with	  a	  variety	  of	  neurodegenerative	  diseases	  like	  Alzheimer,	  Parkinson	  and	  Multiple	  Sclerosis.	  In	  Parkinson,	  a	  degenerative	  disorder	  primarily	  affecting	  dopaminergic	  neurons	  of	  the	  substancia	  nigra,	  gastrointestinal	  dysfunction	  is	  frequently	  noticed	  before	  motor	   symptoms.	   Also,	   α-­‐synuclein	   protein	   aggregates,	   characteristic	   of	  Parkinson	   disease,	   are	   also	   found	   in	   the	   enteric	   nervous	   system.	   Some	  parkinsonian	   patients	   present	   a	   decrease	   in	   the	   Prevotella	   species,	   combined	  with	   an	   increase	   in	   the	   Akkermansia	   muciniphillia	   91.	   The	   Prevotella	   species	  produces	  mucin	   that	   limits	   intestinal	  permeability	  and	   therefore	  helps	  prevent	  bacteria	  translocation	  to	  systemic	  circulation.	  A	  different	  study	  92	  demonstrated	  higher	  levels	  of	  proinflammatory	  bacteria	  and	  lower	  levels	  of	  anti-­‐inflammatory	  bacteria	   in	  Parkinson	  patients	  compared	   to	  healthy	  controls.	  The	  accumulating	  preclinical	  and	  clinical	  data	  suggest	  than	  the	  Microbiota-­‐gut-­‐brain	  axis	  may	  be	  an	  interesting	  additional	  target	  for	  Parkinson	  therapeutics.	  	  Alzheimer,	   also	   a	   neurodegenerative	   disease,	   is	   characterized	   by	   the	  accumulation	   of	   amyloid	   plaques	   and	   tau	   fibrils	   in	   the	   brain.	   It	   has	   been	  associated	  with	  gut	  Microbiota	  dysbiosis	  either	  in	  preclinical	  or	  clinical	  studies.	  Again,	   an	   increase	   in	   the	   levels	   of	   bacteria	   associated	   with	   inflammation	   was	  found,	  combined	  with	  an	  increase	  in	  intestinal	  permeability,	  suggesting	  that	  gut	  Microbiota	   plays	   an	   important	   role	   in	   the	   earlier	   stages	   of	   the	  neuroinflammation	   associated	   with	   Alzheimer	   93.	   Evidence	   is	   growing	   that	  intervening	  in	  the	  Microbiota-­‐gut-­‐brain	  axis,	  either	  with	  prebiotics,	  probiotics	  or	  dietary	  changes	  can	  ameliorate	  this	  neurodegenerative	  disease.	  	  Another	   high	   prevalence	   neurodegenerative	   disease	   is	  Multiple	   Sclerosis	   (MS),	  characterized	   by	   the	   progressive	   loss	   of	   myelin	   in	   axons.	   Similarly	   to	   other	  neurodegenerative	  diseases,	  an	  increase	  in	  intestinal	  permeability	  was	  found	  in	  MS	  patients,	  allowing	  an	  increase	  in	  the	  translocation	  of	  bacteria	  and	  LPS	  to	  the	  systemic	  circulation	  and	  thus	  increasing	  systemic	  inflammation	  94.	  Additionally,	  
when	   compared	   to	   healthy	   controls,	   MS	   patients	   presented	   lower	   levels	   of	  
Faecalibacterium,	  Prevotella	  and	  Anaerostiples	  and	  a	  striking	  depletion	  of	  species	  belonging	  to	  the	  Clostridia	  XIVa	  and	  IV	  Clusters	  95.	  	  Gut	  Microbiota	   dysbiosis	  was	   also	   associated	  with	   psychiatric	   pathologies	   like	  schizophrenia	  whose	  patients	  showed	  significant	  correlations	  between	  increases	  in	  Lactobacillus	  group	  bacteria	  and	  the	  severity	  of	  different	  symptom	  domains	  96.	  	  The	   ever-­‐growing	   information	   regarding	   the	   Microbiota-­‐gut-­‐axis,	   both	   in	  characterization	  and	  in	  mechanistic	  pathways,	  opens	  doors	  to	  the	  identification	  of	   early	   biomarkers	   and	   new	   therapeutic	   targets	   that	   can	   be	   used	   to	   treat	   or	  ameliorate	  central	  nervous	  systems	  diseases.	  Gut	  Microbiota	  modulation,	  though	  in	  need	  of	  more	  robust	  clinical	  data,	  presents	  itself	  as	  a	  promising	  strategy.	  	  2.9	  GUT	  MICROBIOME	  AND	  OTHER	  PATHOLOGIES	  	  Several	   other	   pathologies	   have	   been	   associated	   to	   significant	   changes	   in	   gut	  Microbiota	   even	   though	   it	   is	   not	   clear	   if	   the	   dysbiosis	   is	   their	   cause	   or	   their	  consequence,	  or	  even	  the	  extension	  to	  which	  it	  affects	  the	  pathology.	  Ankylosing	   spondylitis	   (AS)	   is	   a	   type	   of	   arthritis	   that	   is	   referred	   to	   a	   group	   of	  chronic	   immune-­‐mediated	   inflammatory	   diseases	   termed	   as	   seronegative	  spondyloarthropathies	   or	   spondyloarthritis.	   Even	   if	   the	   mechanisms	   remain	  unclear,	  there	  is	  some	  evidence	  that	  gut	  Microbiota	  and	  the	  IL-­‐23/IL-­‐17	  pathway	  are	   pivotal	   in	   the	   pathogenesis	   of	   spondyloarthritides	   97.	   A	   similar	   association	  was	   found	   between	   gut	   dysbiosis	   and	   rheumatoid	   arthritis	   (RA).	   There	   is	   also	  growing	   evidence	   that	   different	   drugs,	   such	   as	   antibiotics	   and	  immunosuppressants,	   can	   influence	  and	  be	   influenced	  by	   the	  Microbiota	   in	  RA	  and	  AS	  patients	  98.	  	  Recently,	   suggestions	   arose	   of	   the	   involvement	   of	   a	   gut-­‐retina	   axis	   in	   the	  protection	   against	   dietary	   glycemia-­‐induced	   age-­‐related	   macular	   degeneration	  (AMD).	  Metabolomics	  revealed	  microbial	  co-­‐metabolites,	  particularly	  serotonin,	  
as	   protective	   against	   AMD	   and	   Bacteroidales	   as	   protective	   towards	   de	   the	  development	  of	  the	  disease	  99.	  Choroidal	  neovascularization	  can	  also	  be	  aggravated	  by	  gut	  Microbiota	  dysbiosis.	  Gut	   dysbiosis	   known	   effects	   of	   heightened	   intestinal	   permeability	   and	   chronic	  low-­‐grade	   inflammation,	   characteristic	   of	   inflammaging,	   associated	   with	  elevated	   production	   of	   IL-­‐6,	   IL-­‐1β,	   TNF-­‐α,	   and	   VEGF-­‐A,	   ultimately	   aggravate	  pathological	  angiogenesis	  100.	  	  Gut	  Microbiota	  dysbiosis	  has	  also	  been	  associated	  with	  dermatological	  diseases	  like	  atopic	  dermatitis	  101	  and	  eczema	  102,	  as	  well	  as	  with	  other	  several	  allergies	  related	  pathologies,	  mainly	  due	  to	  mechanisms	  of	  mucosal	  immune	  tolerance	  103.	  	  Finally,	  another	  very	  interesting	  effect	  of	  gut	  Microbiota	  is	  the	  influence	  it	  plays	  in	  the	  effectiveness	  of	  drugs.	  The	  first	  studies	  of	  alterations	  in	  drug	  effectiveness	  are	  now	  published	  and	  demonstrate	   that	  gut	  Microbiota	   is	  an	  additional	   factor	  that	   should	   be	   taken	   into	   consideration	   when	   prescribing	   a	   drug.	   This	  interaction	   has	   been	   demonstrated	   in	   chemotherapeutics	   104,	   antihypertensive	  drugs	  105,	  antibiotics	  106	  and	  immunotherapeutics	  107,	  and	  is	  naturally	  expected	  to	  interfere	  with	  many	  other	  drugs	  and	  therapeutic	  processes.	  	  3	  -­‐	  CONCLUSION	  	  The	   impact	   of	   Microbiome	   and	   Microbiota	   on	   numerous	   diseases	   has	   been	  increasingly	  documented	  in	  the	  last	  decade.	  	  It	  remains	  doubtful	  if	  dysbiosis	  is	  a	  cause	  or	  a	  consequence	  of	  those	  diseases,	  and	  to	  which	   extension	   it	  may	   affect	   clinical	   result.	  Nevertheless,	   the	  Microbiota	   is	  now	   being	   considered	   a	   “virtual	   organ”,	   with	   its	   metabolic	   and	   immune	  relevance	  becoming	  ever	  more	  clear	  and	  increasingly	  taken	  into	  consideration	  in	  the	  clinical	  approach.	  	  As	   such,	   several	   Microbiota	   modulation	   strategies	   have	   been	   suggested,	  including	  the	  use	  of	  prebiotics,	  probiotics,	  antibiotics,	  dietary	  changes	  and	  faecal	  transplant,	  all	  with	  moderate	  success.	  For	  some	  of	  these	  strategies	  the	  regulatory	  framework	  is	  developing	  together	  with	  the	  knowledge	  increase.	  
Also,	   the	   interaction	   between	  Microbiota	   and	   administered	  medication	   is	   now	  being	   considered,	   as	   clinical	   data	   demonstrate	   that	   drug	   effectiveness	   is	   also	  dependent	  on	  the	  Microbiota	  composition.	  More	   robust	   and	   powerful	   clinical	   studies	   are	   being	   performed	   or	   planned	   in	  order	   to	   better	   understand	   the	   impact	   of	   Microbiota	   and	   its	   modulation.	  Preclinical	   data	   is	   of	   extreme	   relevance	  but	   translation	   to	  humans	  needs	   to	  be	  done	  carefully.	  New	  analytical	  techniques,	  more	  sensitive	  and	  more	  precise,	  will	  similarly	   improve	  our	   insight	   into	   its	   role	   in	   the	  health	   status	  of	   an	   individual,	  not	  only	  regarding	  bacterial	  composition,	  but	  also	  the	  importance	  of	  fungi,	  virus	  and	  phages.	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